Standout Papers

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced P... 2013 2026 2017 2021 464
  1. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (2013)
    C. Warren Olanow, Karl Kieburtz et al. The Lancet Neurology
  2. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial (2019)
    Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology
  3. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis (2020)
    William J. Sandborn, Subrata Ghosh et al. Gastroenterology

Immediate Impact

6 from Science/Nature 79 standout
Sub-graph 1 of 18

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Applied body-fluid analysis by wearable devices
2024 StandoutNature
3 intermediate papers

Works of Ahmed A. Othman being referenced

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
2016
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
2013 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Ahmed A. Othman 319 374 351 613 517 91 2.6k
Kathryn C. Fitzgerald 240 432 688 835 372 158 4.0k
Roberto Pola 468 476 1718 332 258 129 4.2k
Leonardo Iaccarino 52 461 428 352 570 103 2.8k
Monika Baier 800 194 552 665 718 60 4.4k
Luca Durelli 866 747 382 1684 924 113 4.1k
Katherine Dawson 803 628 889 750 658 32 3.4k
Susan A. Burchill 874 227 1427 952 129 79 3.6k
Paolo Gallo 553 475 1333 630 449 104 3.6k
Mazen M. Dimachkie 110 201 596 1581 393 159 3.1k
Jacob Elkins 313 613 206 708 300 75 3.2k

All Works

Loading papers...

Rankless by CCL
2026